ECM
TMO icon

ETrade Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

ETrade Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1.25M Buy
2,824
+294
+12% +$121K 0.02% 317
2020
Q2 		$917K Sell
2,530
-1,357
-35% -$455K 0.02% 379
2020
Q1 		$1.1M Sell
3,887
-787
-17% -$248K 0.03% 272
2019
Q4 		$1.52M Sell
4,674
-344
-7% -$104K 0.03% 256
2019
Q3 		$1.46M Sell
5,018
-5,439
-52% -$1.56M 0.04% 259
2019
Q2 		$3.07M Sell
10,457
-3,094
-23% -$852K 0.08% 146
2019
Q1 		$3.71M Sell
13,551
-574
-4% -$143K 0.11% 112
2018
Q4 		$3.16M Sell
14,125
-628
-4% -$147K 0.1% 111
2018
Q3 		$3.6M Buy
14,753
+159
+1% +$36.6K 0.1% 108
2018
Q2 		$3.02M Sell
14,594
-179
-1% -$38K 0.09% 124
2018
Q1 		$3.05M Sell
14,773
-3,366
-19% -$707K 0.1% 113
2017
Q4 		$3.44M Sell
18,139
-1,338
-7% -$256K 0.11% 100
2017
Q3 		$3.69M Buy
19,477
+374
+2% +$67.7K 0.13% 85
2017
Q2 		$3.33M Sell
19,103
-1,126
-6% -$189K 0.13% 86
2017
Q1 		$3.11M Sell
20,229
-4,217
-17% -$645K 0.13% 89
2016
Q4 		$3.45M Sell
24,446
-2,115
-8% -$312K 0.16% 72
2016
Q3 		$4.22M Sell
26,561
-930
-3% -$143K 0.2% 52
2016
Q2 		$4.06M Sell
27,491
-707
-3% -$104K 0.22% 50
2016
Q1 		$3.99M Sell
28,198
-668
-2% -$89.5K 0.23% 40
2015
Q4 		$4.09M Sell
28,866
-232
-0.8% -$30.9K 0.24% 42
2015
Q3 		$3.56M Buy
29,098
+548
+2% +$71.4K 0.22% 46
2015
Q2 		$3.7M Sell
28,550
-105
-0.4% -$13.7K 0.22% 47
2015
Q1 		$3.85M Buy
28,655
+744
+3% +$95.9K 0.23% 45
2014
Q4 		$3.5M Buy
27,911
+910
+3% +$111K 0.21% 44
2014
Q3 		$3.29M Buy
27,001
+290
+1% +$35.3K 0.21% 48
2014
Q2 		$3.15M Buy
26,711
+3,284
+14% +$386K 0.21% 52
2014
Q1 		$2.82M Buy
23,427
+2,563
+12% +$305K 0.2% 52
2013
Q4 		$2.32M Buy
20,864
+3,815
+22% +$379K 0.18% 60
2013
Q3 		$1.57M Buy
17,049
+3,708
+28% +$335K 0.14% 72
2013
Q2 		$1.13M Buy
+13,341
New +$1.11M 0.12% 75

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ETrade Capital Management's TMO Position: Q3 2020 in Review

ETrade Capital Management increased its Thermo Fisher Scientific (TMO) stake by 12% in Q3 2020, buying an estimated $121K and bringing the position to 2,824 shares worth $1.25M. The position accounts for 0.02% of the portfolio, ranked #317.

ETrade Capital Management first reported a position in TMO in Q2 2013 and has held it in 30 quarters since. The position peaked at $4.22M in Q3 2016. 1,848 funds tracked by Wall St. Rank hold TMO as of Q3 2020.

  • ETrade Capital Management held 2,824 shares of Thermo Fisher Scientific worth $1.25M as of Q3 2020.
  • ETrade Capital Management bought 294 Thermo Fisher Scientific shares in Q3 2020, an estimated $121K.
  • Thermo Fisher Scientific made up 0.02% of ETrade Capital Management's portfolio in Q3 2020, its #317 holding.
  • ETrade Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 30 quarters since.
  • ETrade Capital Management's Thermo Fisher Scientific position peaked at $4.22M in Q3 2016.
  • 1,848 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.